Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Completes Dosing in Phase I/II UTI/Urosepsis Rapid Infusion Trial
Details : R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria. It is under development for the treatment of Urinary tract infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : PT Etana Biotechnologies Indonesia
Deal Size : Undisclosed
Deal Type : Partnership
Recce Pharmaceuticals Forms Strategic Partnership in Southeast Asia for Clinical Programs
Details : Reece will develop RECCE 327 (r327), a new anti-infective, for clinical trials on urinary tract infections, including urosepsis.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 02, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : PT Etana Biotechnologies Indonesia
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Doses First Participants in UTI and Urosepsis Trial
Details : R327 (RECCE-327) is a broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. It is under development for Urinary tract infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 17, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMM-529
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immuron Plans Phase 2 Trial for IMM-529 following FDA Review
Details : IMM-529 is a polyclonal antibody bein investigated for Clostridioides difficile infections as it neutralises localized toxin B at the site of infection.
Product Name : IMM-529
Product Type : Antibody
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : IMM-529
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Announces Safety Approval for 4,000mg Dose in RECCE® 327 Trial
Details : R327 (RECCE-327) is a fast-acting anti-infective targeting Gram-positive and Gram-negative bacteria, including resistant strains, under development for urinary tract infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial Of ReccE® 327
Details : RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative E. coli, which is being investigated for sepsis and complicated/uncomplicated UTIs.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 19, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial Of ReccE® 327 for Infections
Details : RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative E. coli, which is being investigated for sepsis and complicated/uncomplicated UTIs.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 14, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GPN Reports Positive Safety and Immunogenicity Data from Phase 1 Trial of Gamma-PN
Details : Gamma-PN3 is a non-adjuvanted whole cell-pneumococcal vaccine. It is under phase 1/2 clinical development for the treatment of Pneumococcal Infections.
Product Name : Gamma-PN3
Product Type : Vaccine
Upfront Cash : Inapplicable
March 01, 2024
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharma Reports Positive Data from Phase I/II Trial of RECCE® 327 for UTI/Urosepsis
Details : R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria, including resistant forms. It is under development for the treatment of Urinary tract infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is investigated for the treatment of urinary tract infection.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable